摘要
目的:探讨中成药泽桂隆爽胶囊联合α1受体阻滞剂萘哌地尔治疗良性前列腺增生症(BPH)的疗效。方法:门诊BPH患者140例,随机分为治疗组与对照组,每组70例,治疗组口服泽桂癃爽胶囊,每粒0.4 g,每次2粒,每日3次,每晚睡前联合服用萘哌地尔,每次25 mg,每日1次。对照组仅每晚睡前服用萘哌地尔,每次25 mg,每日1次。均治疗8周。观察治疗组与对照组治疗前后夜尿次数、排尿情况、尿流、射程等症状变化及国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、生活质量评分(QOL)、剩余尿及前列腺质量变化。结果:全部患者肝肾功能、血压及心电图均无异常。治疗8周后两组患者的夜尿次数多、排尿无力、尿流细、射程短等症状均有明显好转。与治疗前比较,两组治疗后IPSS和QOL评分降低(P<0.05),Qmax升高(P<0.05),剩余尿显著减少(P<0.05)。治疗组治疗后IPSS、剩余尿低于对照组治疗后(P<0.01),治疗组治疗后Qmax高于对照组治疗后(P<0.01),前列腺质量与单纯应用泽桂癃爽比较虽略降低,但无显著性差异。结论:中成药泽桂癃爽胶囊与萘哌地尔联合应用治疗BPH,可有效改善患者的主观症状与客观指标,无明显毒副作用。提示两种药物联合应用是治疗轻、中度BPH较为理想的药物。
Objective To study the curative effect of ZeGuiLongShuang capsules combined with naftopidil on benign prostatic hyperplasia （BPH） . Methods 140 cases with BPH were randomly divided into treatment group and control group. The patients in treatment group were given ZeGuiLongShuang capsules （once 2 tablets, 3 times a day） combined with naftopidil （once 25 mg, once a day before sleeping）. The patients in control group were given only naftopidil （once 25 rag, once a day before sleeping）. Internatianal-prognosic-scoring-system （IPSS）, uroflowmetry-max （Qmax）, Quality-of-life （QOL）, residual urine and weight of prostate before and after treatment were detected. Results IPSS, Qmax, QOL and residual urine changed in two groups. IPSS, Qmax, QOL and residual urine in treatment group were more significant than those in control group （P〈0.05）. There was little change of weight of prostate. Conclusion There is no remarkable side effect of ZeGuiLongShuang capsules combined with naftopidil. ZeGuiLongShuang capsules combined with naftopidil is highly effective for BPH by decreasing rational symptom and objective index and improving the life quality of patients with BPH.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2009年第5期936-939,共4页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅科技发展计划项目(重点)资助课题(20050908-4)
关键词
前列腺增生
中成药
泽桂隆爽胶囊
萘哌地尔
prostatic heperplasia
chinese patent drugs medicine
ZeGuiLongShuang capsules
Naftopidil
作者简介
李智（1981-），女，吉林省通化市人，医师，医学学士，主要从事药理学研究。
[通讯作者]王伟华（Tel：0431—84995842，E-mail：wei@uro．med．tohoku．ac．jp）
